Institut Bordet - Retour à la page d'accueil
en
I want to donate to research

Philippe Aftimos

Department : Medical oncology, Clinical Trials Conduct Unit (CTCU)
 
philippe.aftimos [at] bordet.be

Publications

Delivering precision oncology to patients with cancer.

Authors : Mateo J, Steuten L, Aftimos P, André F, Davies M, Garralda E, Geissler J, Husereau D, Martinez-Lopez I, Normanno N, Reis-Filho JS, Stefani S, Thomas DM, Westphalen CB, Voest E
Year : 2022
Journal : Nat Med

First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumours.

Authors : Schöffski P, Awada A, de la Bigne AM, Felloussi Z, Burbridge M, Cantero F, Colombo R, Maruzzelli S, Ammattatelli K, de Jonge M, Aftimos P, Dumez H, Sleijfer S
Year : 2022
Journal : Eur J Cancer

FUS::CREM-rearranged malignant epithelioid neoplasm mimicking neuroendocrine neoplasm of unknown primary.

Authors : Demetter P, Awada A, Aftimos P, Liberale G, Jungels C, Gomez-Galdon M, Saiselet M, de Saint Aubain N
Year : 2022
Journal : Histopathology

First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours.

Authors : Robbrecht D, Jungels C, Sorensen MM, Spanggaard I, Eskens F, Fretland SØ, Guren TK, Aftimos P, Liberg D, Svedman C, Thorsson L, Steeghs N, Awada A
Year : 2022
Journal : Br J Cancer

Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors.

Authors : Delord JP, Italiano A, Awada A, Aftimos P, Houédé N, Lebbé C, Pages C, Lesimple T, Dinulescu M, Schellens JHM, Leijen S, Rottey S, Kruse V, Kefford R, Faivre S, Gomez-Roca C, Scheuler A, Massimini G, Raymond E
Year : 2021
Journal : Target Oncol

More publications »

Follow us!

Youtube

The New Jules Bordet Institute.

The New Jules Bordet Institute, located on the university campus of the ULB in Anderlecht, is ready and will soon welcome its first patients. A new state-of-the-art hospital entirely dedicated to the fight against cancer.